for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ACADIA Pharmaceuticals Inc.

ACAD.OQ

Latest Trade

43.52USD

Change

0.25(+0.58%)

Volume

648,722

Today's Range

42.67

 - 

43.98

52 Week Range

23.77

 - 

58.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Acadia Pharmaceuticals Announces U.S. FDA Accepted For Filing Supplemental New Drug Application For Nuplazid

July 20 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES U.S. FDA ACCEPTED FOR FILING THE SUPPLEMENTAL NEW DRUG APPLICATION FOR NUPLAZID® (PIMAVANSERIN) FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS INC - PDUFA DATE SET FOR APRIL 3, 2021 FOR NUPLAZID.ACADIA PHARMACEUTICALS INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE SET FOR APRIL 3, 2021 FOR NUPLAZID.ACADIA PHARMACEUTICALS INC - SNDA IS SUPPORTED BY RESULTS FROM PIVOTAL PHASE 3 HARMONY STUDY.ACADIA PHARMACEUTICALS INC - FDA IS NOT PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING.

Acadia Pharmaceuticals Announces Top-Line Results From The Phase 3 Clarity Study Evaluating Pimavanserin For The Adjunctive Treatment Of Major Depressive Disorder

July 20 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM THE PHASE 3 CLARITY STUDY EVALUATING PIMAVANSERIN FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.ACADIA PHARMACEUTICALS INC - STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - POSITIVE RESULTS WERE OBSERVED ON KEY SECONDARY ENDPOINT, CLINICAL GLOBAL IMPRESSION - SEVERITY (CGI-S) SCORE.ACADIA PHARMA - COMBINED EFFICACY AND SAFETY ANALYSIS WAS PRE-SPECIFIED PRIOR TO DATA UNBLINDING FOLLOWING FEEDBACK FROM FDA.ACADIA PHARMACEUTICALS INC - IN STUDY, PIMAVANSERIN WAS GENERALLY WELL-TOLERATED WHEN ADDED TO EXISTING ANTIDEPRESSANT THERAPY.ACADIA PHARMACEUTICALS INC - POSITIVE RESULTS WERE OBSERVED ON KEY SECONDARY ENDPOINT.ACADIA PHARMACEUTICALS INC - SIMILAR RATES OF ADVERSE EVENTS WERE OBSERVED BETWEEN PIMAVANSERIN & PLACEBO.

Acadia Submits Supplemental NDA To U.S. FDA For Nuplazid For Treatment Of Delusions Associated With Dementia-Related Psychosis

June 15 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR NUPLAZID® (PIMAVANSERIN) FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR NUPLAZID® (PIMAVANSERIN) FOR TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS - SUBMISSION BASED ON POSITIVE RESULTS FROM PHASE 3 HARMONY STUDY.

Acadia Pharmaceuticals Reports First Quarter 2020 Financial Results

May 7 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.57.Q1 SALES $90.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $91.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.SEES 2020 REVENUE GUIDANCE REDUCED BY APPROXIMATELY 5% DUE TO CURRENTLY ANTICIPATED COVID-19 IMPACT.SEES 2020 NUPLAZID NET SALES GUIDANCE IS DECREASED TO $420 TO $450 MILLION.2020 YEAR-END CASH, CASH EQUIVALENTS, AND INVESTMENT SECURITIES OF $470 TO $500 MILLION IS UNCHANGED.

Acadia Pharmaceuticals Reports Q4 Loss Per Share $0.34

Feb 26 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.34.SEES FY 2020 REVENUE UP ABOUT 34 PERCENT.SEES FY 2020 SALES $440 MILLION TO $470 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.QTRLY REVENUE $98.3 MILLION VERSUS $59.6 MILLION.Q4 REVENUE VIEW $96.8 MILLION -- REFINITIV IBES DATA.SEES 2020 GAAP RESEARCH AND DEVELOPMENT TO BE BETWEEN $270 MILLION AND $285 MILLION.SEES 2020 GAAP SG&A IS EXPECTED TO BE BETWEEN $440 MILLION AND $460 MILLION.SEES 2020 YEAR-END CASH, CASH EQUIVALENTS, AND INVESTMENT SECURITIES TO BE BETWEEN $470 MILLION AND $500 MILLION.

ACADIA Pharmaceuticals Says Pivotal Phase 3 Harmony Study Showed Pimavanserin Reduced Risk Of Psychotic Relapse

Dec 4 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 HARMONY STUDY SHOWED PIMAVANSERIN REDUCED RISK OF PSYCHOTIC RELAPSE.PIMAVANSERIN MET PRIMARY ENDPOINT OF STUDY BY SIGNIFICANTLY REDUCING RISK OF PSYCHOTIC RELAPSE BY 2.8 FOLD OVER PLACEBO.PIMAVANSERIN MET KEY SECONDARY ENDPOINT BY SIGNIFICANTLY REDUCING RISK OF DISCONTINUATION FOR ANY REASON BY 2.2 FOLD OVER PLACEBO.PIMAVANSERIN 34 MG WAS WELL TOLERATED WHEN GIVEN LONG-TERM IN ELDERLY POPULATION WITH SIGNIFICANT COMORBIDITIES.NUPLAZID (PIMAVANSERIN) NOT APPROVED FOR TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.MOST COMMON ADVERSE REACTIONS FOR NUPLAZID AND GREATER THAN PLACEBO INCLUDE PERIPHERAL EDEMA, NAUSEA, HALLUCINATION.

ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results

Oct 30 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.29.Q3 SALES $94.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $88.5 MILLION.SEES FY 2019 SALES $330 MILLION TO $340 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $326.8 MILLION -- REFINITIV IBES DATA.

Acadia Pharmaceuticals Prices Underwritten Public Offering Of 6.25 Mln Shares At $40/Shr

Sept 17 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 6.25 MILLION SHARES OF COMMON STOCK AT PRICE TO PUBLIC OF $40.00 PER SHARE.

Acadia Pharmaceuticals - Intends To Offer And Sell $250 Million Of Its Common Stock

ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - INTENDS TO OFFER AND SELL $250 MILLION OF ITS COMMON STOCK.

Acadia Pharmaceuticals Announces Pivotal Phase 3 Harmony Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis

Sept 9 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 HARMONY TRIAL STOPPED EARLY FOR POSITIVE EFFICACY AS PIMAVANSERIN MEETS THE PRIMARY ENDPOINT IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS INC - PHASE 3 HARMONY STUDY MET ITS PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN ACHIEVED ROBUST STATISTICAL SUPERIORITY OVER PLACEBO IN STUDY.ACADIA PHARMA - STUDY TO BE STOPPED EARLY BASED ON PRE-SPECIFIED STOPPING CRITERIA REQUIRING ONE-SIDED P-VALUE LESS THAN 0.0033 ON STUDY'S PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - COMPANY IS PLANNING TO MEET WITH FDA REGARDING A SUPPLEMENTAL NDA SUBMISSION IN 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up